Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/24/2025

Management of Gastrointestinal Bleeding

Introduction to Management

  • In patients with gastrointestinal bleeding and recent drug-eluting stent (DES) implantation, aspirin should be continued while temporarily interrupting the P2Y12 receptor inhibitor, with urgent endoscopy performed within 24 hours and resumption of dual antiplatelet therapy as soon as hemostasis is achieved, as recommended by the European Society of Cardiology 1

Aspirin and P2Y12 Inhibitor Management

  • Aspirin should be continued for secondary prevention if possible, but temporarily held if hemodynamically unstable with life-threatening bleeding, as recommended by the European Society of Cardiology 1
  • P2Y12 receptor inhibitor (clopidogrel, ticagrelor, prasugrel) should be temporarily interrupted in patients with gastrointestinal bleeding and recent DES implantation, with plans to reinstate within 5 days to minimize stent thrombosis risk, as recommended by the European Society of Gastroenterology 1, 2

Endoscopy and Hemostasis

  • Urgent endoscopy should be performed within 24 hours of presentation in patients with gastrointestinal bleeding and recent DES implantation, with very early endoscopy (<12 hours) for patients with hemodynamic instability, as recommended by the European Society of Gastroenterology and the European Heart Society 2, 3
  • Hemodynamic stabilization with IV fluids targeting mean arterial pressure >65 mmHg and restrictive transfusion strategy with target hemoglobin >7 g/dL should be performed 4

Resumption of Dual Antiplatelet Therapy

  • Dual antiplatelet therapy should be resumed as soon as hemostasis is achieved in patients with very high thrombotic risk (DES <6 weeks), and within 5 days in patients with high thrombotic risk (DES 6 weeks-6 months) and moderate-low risk (DES >6 months), as recommended by the European Society of Gastroenterology and the European Society of Cardiology 1, 3

Proton Pump Inhibitor Therapy

  • Proton pump inhibitor (PPI) therapy should be added to all patients on dual antiplatelet therapy, as recommended by the European Heart Society and the American Heart Association 2, 5

Risk of Stent Thrombosis

  • The risk of stent thrombosis is highest within the first 6 weeks after DES implantation, and remains high from 6 weeks to 6 months, then remains constant thereafter, as reported by the European Society of Gastroenterology 3
  • Discontinuation of P2Y12 inhibitor is a strong independent risk factor for stent thrombosis 6

Anticoagulation Management

  • Anticoagulants should be withheld to facilitate hemostasis, and resumed once adequate hemostasis is achieved, with optimal timing for warfarin at 7 days after bleeding has stopped, and consideration of low molecular weight heparin bridging at 48 hours after hemostasis for patients with metallic heart valves or recent venous thromboembolism (<3 months) 1, 3
  • Direct oral anticoagulants (DOACs) should be resumed after adequate hemostasis is achieved, without heparin bridging, as recommended by the European Society of Gastroenterology 3

Clinical Decision-Making

  • A systematic review showed that patients who resumed anticoagulation after gastrointestinal bleeding had lower risk of thromboembolism (RR: 0.30) and death (RR: 0.51) but increased risk of recurrent bleeding (RR: 1.91) 7
  • Consultation with a multidisciplinary team including gastroenterology, cardiology, and hematology is recommended when making decisions about anticoagulation management, especially for patients with high thrombotic risk who may benefit from earlier resumption of anticoagulation despite the increased bleeding risk 4, 7